Claims
- 1. A pharmaceutical composition for hydrating lung mucus secretions, the composition comprising:a pharmaceutically acceptable carrier; and a compound selected from the group consisting of uridine 5′-diphosphate, uridine 5′-O-(2-thiodiphosphate), 2-deoxyuridine 5′-diphosphate, 4-mercaptouridine 5′-diphosphate, and the pharmaceutically acceptable salts thereof, wherein the compound is present in an amount effective to hydrate lung mucus secretions.
- 2. The pharmaceutical composition according to claim 1 wherein the pharmaceutically acceptable carrier is selected from the group consisting of solid carriers and liquid carriers.
- 3. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition further comprises a propellant.
- 4. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is an aerosol suspension comprising respirable particles of the compound and the pharmaceutically acceptable carrier.
- 5. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is an aerosol suspension comprising respirable dry particles of the compound and the pharmaceutically acceptable carrier.
- 6. A pharmaceutical composition for hydrating lung mucus secretions, the composition comprising:a pharmaceutically acceptable carrier; and a compound selected from the group consisting of 3′-deoxyuridine-5′-diphosphate, 5-(1-phenylethynyl)-uridine 5′-diphosphate, 5-methyluridine 5′-diphosphate, 4-hexylthiouridine 5′-diphosphate, 4-mercaptouridine 5′-diphosphate, 4-methoxyuridine 5′-diphosphate, 4-hexyloxyuridine 5′-diphosphate, N,N-dimethylcytidine 5′-diphosphate, N-hexylcytidine 5′-diphosphate, and the pharmaceutically acceptable salts thereof, wherein the compound is present in an amount effective to hydrate lung mucus secretions.
- 7. The pharmaceutical composition according to claim 6 wherein the pharmaceutically acceptable carrier is selected from the group consisting of solid carriers and liquid carriers.
- 8. The pharmaceutical composition according to claim 6, wherein the pharmaceutical composition further comprises a propellant.
- 9. The pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is an aerosol suspension comprising respirable particles of the compound and the pharmaceutically acceptable carrier.
RELATED APPLICATIONS
This application is a continuation of U.S. application Ser. No. 09/143,297, filed Aug. 28, 1998, now U.S. Pat. No. 6,143,279, issued Nov. 7, 2000, which claims the benefit of U.S. Provisional Application No. 60/057,064, filed Aug. 29, 1997, which application is incorporated herein in its entirety.
GOVERNMENT SUPPORT
This invention was made with United States government support under grant number #2PO1 HL32322-11A1 from the National Institutes of Health. The United States government has certain rights in this invention
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
6022527 |
Boucher et al. |
Feb 2000 |
A |
6143279 |
Boucher et al. |
Nov 2000 |
A |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/057064 |
Aug 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09/143297 |
Aug 1998 |
US |
Child |
09/645161 |
|
US |